Neogenomics Stock

Neogenomics Non-Current Assets

The Non-Current Assets of Neogenomics (NEO) as of Aug 3, 2026 is 307.30 M USD. In the previous year, Non-Current Assets was 266.33 M USD — a change of 15.38% (higher).

Non-Current Assets

307.30 MUSD

YoY

15.38%

Last updated:

Non-Current Assets of Neogenomics is 2026 307.30 M USD. Non-Current Assets of Neogenomics was 2025 266.33 M USD. It decreases by 15.38% higher compared to the previous year.
Access this data via the Eulerpool API

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

Non-Current Assets of Neogenomics is 307.30 M USD in 2026.

Non-Current Assets of Neogenomics changed from 266.33 M USD to 307.30 M USD, representing a 15.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Non-Current Assets Neogenomics since 2006 – with annual values, charts, and detailed analysis.

Non-current assets are long-term resources not expected to be converted to cash within one year, including property, equipment, and long-term investments.

Non-Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Non-Current Assets's Neogenomics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Neogenomics

All Key Metrics — Neogenomics